Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
CAPS Rating:
A biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions.
A biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions.
Recs
I believe that this company's new cancer drug will draw in many investors over the next few months and the drug itself, which is in FDA review, looks like a definite winner. I suspect this stock to hit $65 , maybe as high as $80 by Q4 07.
And what if this cancer drug is not successful. This co is projected to lose $3.96 a share this year.If they dont start making money they will need to float more shares.$80 yeah sure. Take a few of these hyped up biotechs losing big money and practically no book value you will find it easy to beat the s&p. Its a crapshoot as to winning with this stock.
Drug was approved in March in the US and in June for Europe. First quarter of sales was expected to be $3mm and it turn out to be $9.8mm. This quarter sales are expected to be $15mm and we will learn in the end of October if they beat again. Right now with the stock at $69/sh it looks like the call of $80/sh by the 4Q07 looks like the right one...
You nailed this one. Kudos. I'm still amazed the street keeps propping this up. I wish I could put my red thumb on now instead of last year.